|
May 8
|
QuidelOrtho Reports First Quarter 2024 Financial Results
|
|
May 3
|
QuidelOrtho names ex-Abbott exec Brian Blaser as CEO
|
|
May 2
|
QuidelOrtho Appoints Brian J. Blaser as President and Chief Executive Officer
|
|
Apr 17
|
QuidelOrtho To Report First Quarter 2024 Financial Results
|
|
Apr 10
|
QuidelOrtho Adds Fentanyl Test to Its Vitros® Systems as a MicroTip® Partnership Assay
|
|
Apr 3
|
This QuidelOrtho Insider Increased Their Holding By 54% Last Year
|
|
Apr 3
|
QuidelOrtho pulls FDA submission of 4-virus test
|
|
Apr 2
|
QuidelOrtho Receives FDA 510(k) Clearance for Its QuickVue® COVID-19 Test
|
|
Mar 14
|
QuidelOrtho to lay off employees after firing CEO
|
|
Mar 6
|
QuidelOrtho Receives Health Canada Approval for Quidel® Triage® PLGF Test for Laboratory Use in Canada
|
|
Dec 26
|
Investors in QuidelOrtho (NASDAQ:QDEL) have unfortunately lost 59% over the last three years
|
|
Dec 22
|
QuidelOrtho to Present at 42nd Annual J.P. Morgan Healthcare Conference
|
|
Dec 20
|
QuidelOrtho Receives 510(K) Clearance for Savanna® Multiplex Molecular Platform and Savanna® HSV 1+2/VZV PCR Assay
|